Stocks and Investing Stocks and Investing
Tue, May 17, 2022

Andrew Fein Maintained (SYRS) at Strong Buy with Decreased Target to $100 on, May 17th, 2022


Published on 2024-10-27 21:08:15 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Maintained "Syros Pharmaceuticals, Inc." (SYRS) at Strong Buy with Decreased Target from $150 to $100 on, May 17th, 2022.

Andrew, nor any peers, have made any analyst calls on SYRS in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources